Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13715363 | 0.90 | SMPD1 (0.43) | SMN1; SMN2RAB9AALDH1A1LMNANPC1 | |
| SCHEMBL3880726 | 0.87 | FFAR4 (0.54) | SMN1; SMN2FFAR1FFAR4KMT2A | |
| SCHEMBL1202809 | 0.79 | RAB9A (0.42) | SMN1; SMN2RAB9AALDH1A1LMNANPC1 | |
| SCHEMBL3858317 | 0.78 | RAB9A (0.50) | SMN1; SMN2RAB9AFFAR4ALDH1A1KMT2A | |
| SCHEMBL13715544 | 0.77 | FFAR4 (0.48) | SMN1; SMN2RAB9AFFAR1FFAR4NPC1 | |
| SCHEMBL3879416 | 0.77 | GAA (0.47) | SMN1; SMN2FFAR1LMNAKMT2ATHRB | |
| SCHEMBL16115915 | 0.76 | CTSA (0.56) | — | |
| SCHEMBL17262511 | 0.75 | FFAR1 (0.41) | FFAR1LMNAKMT2ATHRB | |
| SCHEMBL27821070 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9AALDH1A1KMT2AHPGD | |
| SCHEMBL2505240 | 0.74 | KMT2A (0.49) | SMN1; SMN2FFAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2139843-B1 | SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS | AMGEN INC (US) | 2013-12-25 | — | — | EP | disclosed |
| US-7572934-B2 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | AMGEN INC. (US) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111859-A1 | Substituted biphenyl GPR40 modulators | GPR119, GPR65, GPR55 | SMN1; SMN2 4745/4885RAB9A 3716/4885FFAR1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.